50 -8 (70) 2024 - Bakhramova A.A. - CARBOHYDRATE METABOLISM DISORDERS AS A CARDIOVASCULAR RISK FACTOR

CARBOHYDRATE METABOLISM DISORDERS AS A CARDIOVASCULAR RISK FACTOR

Bakhramova A.A. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

One of the most significant risk factors for ischemic heart disease is diabetes. However, the literature on the role of IGT as a risk factor for coronary artery disease varies significantly. Meanwhile, in some cases, IGT may precede the development of diabetes and, in a certain sense, it can be considered as a “pre-illness” state in relation to diabetes. Hyperglycemia, including hidden ones, often occurs with hyperinsulinemia, which is considered one of the components of the “metabolic” syndrome, which plays an important role in the formation of cardiovascular diseases, including coronary artery disease.

Key words: Blood pressure, hyperlipidemia, obesity, diabetes mellitus.

First page

271

Last page

277

For citation:Bakhramova A.A. - CARBOHYDRATE METABOLISM DISORDERS AS A CARDIOVASCULAR RISK FACTOR//New Day in Medicine 8(70)2024 271-277 https://newdayworldmedicine.com/en/new_day_medicine/8-70-2024

List of References

  1. Abdukhakimova N.A. Features of the clinical course of gout in metabolic syndrome // Ph.D. diss. Tashkent, 2011. P. 152.
  2. Akbarova M., Mamasoliev N.S. Epidemiological, clinical, biorhythmological and preventive aspects of chronic heart failure in the extreme continental climate of the Fergana Valley/V-Congress of Cardiologists of the CIS countries in the journal Cardiology of the CIS. 2005;3(2):17.
  3. Tursunov Kh.Kh., Babich S.M. Features of the course of IHD in the extreme continental climate of the Fergana Valley of Uzbekistan //Modern problems of science and education. 2008;3:31-34.
  4. Kamilova U.K., Rasulova Z.D. Study of the comparative effectiveness of the effect of losartan and lisinopril on glomerulo-tubular markers of renal dysfunction in patients with chronic heart failure. //Cardiovascular therapy and prevention. 2015;14(2):41-45. https://doi.org/10.15829/1728-8800-2015-2-41-45
  5. Shagazatova B.Kh., Assessment of the quality of outpatient monitoring of patients with diabetes mellitus // Medical Affairs, 2013.
  6. Baxriddinovna, R. D., & Shavkat kizi, V. S. (2023). Metabolic Syndrome and Pharmacoeconomy (Review). //European journal of innovation in nonformal education, 2023;3(3):69-74. Retrieved from https://inovatus.es/index.php/ejine/article/view/1531
  7. American Diabetes Association. Prevention or delay of type 2 diabetes. //Diabetes Care. 2017;40 (Suppl 1): S44–S47.
  8. Aspry KE, Van Horn L, Carson JAS, et al.: Medical Nutrition Education, Training, and Competencies to Advance Guideline-Based Diet Counseling by Physicians: A Science Advisory from the American Heart Association. //Circulation. 2018;137(23):e821–e841. 10.1161/CIR.0000000000000563.
  9. Barrett-Connor E, Khaw KT. Diabetes mellitus: an independent risk factor for stroke? //Am J Epidemiol 1988;128:116-23. 10.1093/oxfordjournals.aje.a114934
  10. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. //Lancet. 2005;365(9467):1333-46.
  11. Frd, E. S., Giles, W. H. Dietz, W. H. Prevalence the metabоlic syndrоme amng US adults: findings frm the third Natinal Health and Nutritin Examinatin Survey. //JAMA 2002;287:356-359.
  12. Zinman B, Wanner C, Lachin JM, et al; EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. //N Engl J Med. 2015;373:2117-2128.
  13. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. //Ann Intern Med. 2016;165:305-315.
  14. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of diabetes. //Diabetologia. 2005;48(9):1684-99.
  15. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. //Circulation. 2005;112(17):2735-52.
  16. Lu Y, Hajifathalian K, Ezzati M, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. //Lancet 2014;383:970–83. 10.1016/S0140-6736(13)61836-X.

    file

    download